ES2053456T3 - Un procedimiento para preparar un compuesto reactivo de alto peso molecular. - Google Patents

Un procedimiento para preparar un compuesto reactivo de alto peso molecular.

Info

Publication number
ES2053456T3
ES2053456T3 ES87102123T ES87102123T ES2053456T3 ES 2053456 T3 ES2053456 T3 ES 2053456T3 ES 87102123 T ES87102123 T ES 87102123T ES 87102123 T ES87102123 T ES 87102123T ES 2053456 T3 ES2053456 T3 ES 2053456T3
Authority
ES
Spain
Prior art keywords
compound
molecular weight
high molecular
preparing
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87102123T
Other languages
English (en)
Inventor
Miki C O Sumitomo Kagak Kurami
Yoshifumi Shirakami
Keietsu Takahashi
Nobuo Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Original Assignee
Nihon Medi Physics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61315089A external-priority patent/JP2548711B2/ja
Application filed by Nihon Medi Physics Co Ltd filed Critical Nihon Medi Physics Co Ltd
Application granted granted Critical
Publication of ES2053456T3 publication Critical patent/ES2053456T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN AGENTE TERAPEUTICO O PARA DIAGNOSTICO RADIACTIVO, QUE CONTIENE COMPUESTOS DE ELEVADO PESO MOLECULAR, MARCADO CON UN ELEMENTO METALICO, QUE COMPRENDE UNA UNIDAD DE (1) UN COMPUESTO DE POLIAMINA QUE TIENE POR LO MENOS TRES GRUPOS AMINO EN LAS CADENAS LATERALES POR MOLECULA, POR LO MENOS DOS UNIDADES DE (2) UN COMPUESTO FORMADO DE QUELATOS QUE TIENE UN GRUPO CARBOXILO, POR LO MENOS UNA UNIDAD DE (3) UNA SUSTANCIA FISIOLOGICAMENTE ACTIVA Y (4) ELEMENTOS METALICOS RADIACTIVOS POR LO MENOS, ESTANDO COMBINADAS CADA UNIDAD DEL COMPUESTO FORMADOR DE QUELATOS (2) Y LA SUSTANCIA FISIOLOGICAMENTE ACTIVA (3) CON CUALQUIERA DE LOS GRUPOS AMINO EN LAS CADENAS LATERALES DEL COMPUESTO POLIAMINA (1) Y SIENDO QUELATADOS CADA UNO DE LOS ELEMENTOS METALICOS RADIACTIVOS (4) AL COMPUESTO FORMADOR DE QUELATOS.
ES87102123T 1986-02-14 1987-02-14 Un procedimiento para preparar un compuesto reactivo de alto peso molecular. Expired - Lifetime ES2053456T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3162286 1986-02-14
JP61315089A JP2548711B2 (ja) 1986-02-14 1986-12-31 アミノ基と２官能性配位子を有する反応性高分子化合物とその利用

Publications (1)

Publication Number Publication Date
ES2053456T3 true ES2053456T3 (es) 1994-08-01

Family

ID=26370126

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87102123T Expired - Lifetime ES2053456T3 (es) 1986-02-14 1987-02-14 Un procedimiento para preparar un compuesto reactivo de alto peso molecular.

Country Status (7)

Country Link
US (1) US4855353A (es)
EP (1) EP0233619B1 (es)
AU (1) AU593611B2 (es)
CA (1) CA1266344A (es)
DE (1) DE3783242T2 (es)
DK (1) DK172629B1 (es)
ES (1) ES2053456T3 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172391B1 (da) * 1986-12-30 1998-05-18 Nihon Mediphysics Co Ltd Højmolekylær forbindelse til anvendelse som ikke-radioaktiv bærer, radioaktivt mærket højmolekylær forbindelse, fremgangsmåde til fremstilling deraf og fremgangsmåde til forbedret mærkning af en asialoglycoproteinacceptor-dirigerende forbindelse
DE3710730A1 (de) * 1987-03-31 1988-10-20 Schering Ag Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5250702A (en) * 1988-06-07 1993-10-05 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
GR1002475B (el) * 1988-12-05 1996-11-26 Novartis Ag (Novartis Sa) (Novartis Inc.) Μεθοδος παρασκευης πεπτιδικων παραγωγων.
US5028339A (en) * 1989-01-23 1991-07-02 Clark Iii William T Polymer matrix and method for retaining reactants in a polymer matrix
US4959148A (en) * 1989-01-23 1990-09-25 Clark Iii William T Method and apparatus for specific affinity enhanced transport bioreactor
US5914095A (en) * 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
AU628988B2 (en) * 1989-05-04 1992-09-24 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors and complexes therefor
US5230883A (en) * 1989-05-04 1993-07-27 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors using polylysine complexes
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
GB9320277D0 (en) * 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
US5972307A (en) * 1989-10-23 1999-10-26 Nycomed Salutar, Inc. Dichelants
DE4115789A1 (de) * 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
AU3592193A (en) * 1992-01-14 1993-08-03 Steve Pandian Tumor imaging agent
DE4235412A1 (de) * 1992-10-21 1994-04-28 Metallgesellschaft Ag Verfahren zum Vergasen von brennbare Bestandteile enthaltenden Abfallstoffen
WO1994017829A1 (en) * 1993-02-02 1994-08-18 Neorx Corporation Directed biodistribution of small molecules
US5428156A (en) * 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US5429726A (en) * 1993-04-30 1995-07-04 The Yellow Springs Instrument Company, Inc. Methods for reducing level of interferants in biosensor systems and solutions used in these methods
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
ES2126695T3 (es) * 1993-10-22 1999-04-01 Nihon Mediphysics Co Ltd Peptido que tiene afinidad hacia la inflamacion y medio diagnostico radiactivo que lo contiene.
US5766839A (en) * 1994-06-17 1998-06-16 Ysi Incorporated Processes for preparing barrier layer films for use in enzyme electrodes and films made thereby
US5958372A (en) * 1994-06-28 1999-09-28 Nycomed Imaging As Low viscosity chelating polymers for diagnostic imaging
US5556939A (en) * 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US5632969A (en) * 1994-10-13 1997-05-27 Merck & Co., Inc. N3 S2 chelating ligands optionally radiolabelled with Tc or Re, useful for diagnostic or therapeutic applications
US5801228A (en) * 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
US5762909A (en) * 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6020052A (en) * 1996-07-30 2000-02-01 Ysi Incorporated Laminated membrane structure for polarographic measurement and methods of making said structures
US6896874B2 (en) * 1998-05-26 2005-05-24 Wisconsin Alumni Research Foundation MR-signal emitting coatings
US6361759B1 (en) 1998-05-26 2002-03-26 Wisconsin Alumni Research Foundation MR signal-emitting coatings
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
CA2452288A1 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
US20040024317A1 (en) * 2002-07-31 2004-02-05 Uzgiris Egidijus E. Method for assessing capillary permeability
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
DE60323677D1 (de) 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
US20040253292A1 (en) * 2003-04-23 2004-12-16 Wisconsin Alumni Research Foundation MR-signal emitting coatings
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US8457712B2 (en) * 2005-12-30 2013-06-04 Wisconsin Alumni Research Foundation Multi-mode medical device system and methods of manufacturing and using same
US20070156042A1 (en) * 2005-12-30 2007-07-05 Orhan Unal Medical device system and method for tracking and visualizing a medical device system under MR guidance
EP1973947A2 (en) * 2006-01-20 2008-10-01 Welson Pharmaceuticals, Inc. Immunoconjugates with improved efficacy for the treatment of diseases
US8532742B2 (en) * 2006-11-15 2013-09-10 Wisconsin Alumni Research Foundation System and method for simultaneous 3DPR device tracking and imaging under MR-guidance for therapeutic endovascular interventions
DE102007002726A1 (de) 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US20080183070A1 (en) * 2007-01-29 2008-07-31 Wisconsin Alumni Research Foundation Multi-mode medical device system with thermal ablation capability and methods of using same
US8412306B2 (en) * 2007-02-28 2013-04-02 Wisconsin Alumni Research Foundation Voltage standing wave suppression for MR-guided therapeutic interventions
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56125317A (en) * 1980-03-08 1981-10-01 Nippon Mejifuijitsukusu Kk Stable radioactive diagnosticum with radioactive metallic mark
JPS5850656B2 (ja) * 1980-04-10 1983-11-11 財団法人生産開発科学研究所 両性ポリアミド樹脂
US4511550A (en) * 1982-09-07 1985-04-16 Nihon Medi-Physics Co., Ltd. 1-(p-Substituted or unsubstituted aminoalkyl)phenylpropane-1,2-dione bis(thiosemicarbazone) derivatives, and their production and use
JPS59215321A (ja) * 1983-05-23 1984-12-05 Sumitomo Chem Co Ltd 二官能性配位子化合物を結合した反応性高分子
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group

Also Published As

Publication number Publication date
AU6878287A (en) 1987-08-20
EP0233619A1 (en) 1987-08-26
DK75687D0 (da) 1987-02-13
AU593611B2 (en) 1990-02-15
DE3783242D1 (de) 1993-02-11
EP0233619B1 (en) 1992-12-30
DK75687A (da) 1987-08-15
DK172629B1 (da) 1999-03-22
CA1266344A (en) 1990-02-27
DE3783242T2 (de) 1993-04-29
US4855353A (en) 1989-08-08

Similar Documents

Publication Publication Date Title
ES2053456T3 (es) Un procedimiento para preparar un compuesto reactivo de alto peso molecular.
ATE2667T1 (de) Antidepressiv wirkende derivate des trans-4phenyl-1,2,3,4-tetrahydro-1-naphthalin-amins und pharmazeutische zusammensetzungen daraus.
IT1205978B (it) Derivati di dicloroanilina,composizioni farmaceutiche che li contengono e procedimento per produrli
SE8008333L (sv) Komposition for behandling av keratinfibrer baserad pa amfotera och anjoniska polymerer
IL49028A (en) Water-soluble, polymerized, crosslinked, stromal-free hemoglobin,process for preparing the same and pharmaceutical composition containing the same
BR7604460A (pt) Processo para a preparacao de n-(3-trifluor-metil-4-halogeno-fenil)-n'-benzoil-ureias,e composicoes inseticidas a base destas
BR7600621A (pt) Composicao de catalisadores de carbodiimidizacao,insoluveis,de elevado peso molecular e processo para a preparacao dos mesmos
IT8422785A1 (it) Derivati del benzossazolone e del benzotiazolone, procedimenti per la loro preparazione e composizione farmaceutica che li contiene
NO880179D0 (no) Polymerkomplekser, fremgangsmaate for fremstilling av disse, og farmasoeytiske midler inneholdende disse.
IT1203647B (it) Uree e tiouree sostituite aventi attivita' antiaterosclerotica,procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
FI882278A0 (fi) Parannettuja kromikatalyyttikoostumuksia ja polymerointimenetelmä, jossa niitä käytetään
ES2082771T3 (es) Ligandos y complejos cationicos de los mismos con tecnecio-99m.
IT8348743A0 (it) Derivati di 2,5-diammino-1,4-diazolo,procedimento per prepararli e composizioni farmaceutiche che licontengono
IT8319027A0 (it) Derivati amino-alchil-solfonici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
FI880582A (fi) Paperinvalmistuksessa käytettävät uudet valmisteet
BR7600881A (pt) Composicao catalisadora e processo para preparacao da mesma
SE393608B (sv) Som rontgenkontrastmedel anvendbara n-(3-pyrrolidinyliden-(2')-amino-2,4,6-trijodbensoyl)-aminosyror och sett for deras framstellning
IT8621857A0 (it) Cinnamilammine, processo per laloro preparazione e composizioni farmaceutiche che le contengono.
BE763731A (fr) Perfluoropolyethers modifies dans la chaine polymere et procedepour leur preparation
DE69512313D1 (de) Pseudopeptidderivate der Neurokinine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
SU839802A1 (ru) Горочна рельсова цепь
IT8621836A0 (it) Nuovi derivati del catecolo, procedimento per la loro preparazione e composizione terapeutiche che li contengono.
ES550285A0 (es) Procedimiento para preparar derivados de acidos aziridin-2- carboxilicos substituidos en n
ES2039516T3 (es) Empleo de los enantiomeros de la propafenona para la obtencion de medicamentos.
IT1213568B (it) Derivati imidazolici adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 233619

Country of ref document: ES